Sparks - OSE Immunotherapeutics

More on this equity

OSE (PAR: OSE) – Phase II Combi-TED trial completes enrolment

OSE Immunotherapeutics and the FoRT Foundation (an Italian non-profit foundation) have confirmed that patient enrolment is complete for the Phase II Combi-TED trial (n=105). This is an investigator-initiated study evaluating OSE’s lead cancer vaccine, Tedopi, in combination with nivolumab or docetaxel in patients with non-small cell lung cancer (NSCLC). Top-line results are anticipated in H226, consistent with prior guided timelines.

We note that this differs from OSE’s lead internal programme, the Phase III ARTEMIA trial, which is focused on evaluating Tedopi as a monotherapy in NSCLC.

For a more detailed overview of OSE’s active and diverse clinical pipeline, please see our recently published update note.

Next Sparks Commentary in this sector >

Latest

Industrials | Comment

09.09.25

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: Climate accountability – hidden emissions or financial reality?

MediaWatch – A two-tier story

Inside the mind of the investor: Mutares

Audiovisual

Latest

Global Fashion Group – executive interview

OSE Immunotherapeutics – executive interview

Uncovering Trusts – Law Debenture Corporation – A unique combination of an ‘multi-cap’ investment portfolio and independent professional services

About Edison

About Edison

Careers

Sparks - OSE Immunotherapeutics

Latest

Metlen (LSE:MTLN) – H125 results and FY25 guidance maintained

Concurrent (AIM: CNC) expects to beat FY25 consensus

Victoria (LSE:VCP) – AGM statement – no change in trading conditions

OPAP (ASE: OPAP) – Good growth in H125 and on track to deliver FY25 guidance

Severfield (LSE: SVR) – FY26 expectations remain on track

Subscribe to Edison